This may be extended to support a similar approach within the metastatic HR+/HER2-negative breast cancer population, recommending delaying chemotherapy until the benefit of hormonal therapy lessens, tumor becomes refractory to hormonal therapy, and/or a visceral crises is imminent8. The gene discussed is ERBB2; the disease is neoplasm.